>30 Percent With Migraine Experience Migraine-Related Stigma Often

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Jan. 18, 2024 -- More than 30 percent of individuals with migraine experience migraine-related stigma often or very often, according to a study published online Jan. 17 in Neurology.

Robert E. Shapiro, M.D., Ph.D., from the Larner College of Medicine at the University of Vermont in Burlington, and colleagues examined the association between migraine-related stigma with migraine outcomes in a study involving people identified with active migraine using a validated migraine diagnostic questionnaire. The frequency of experiencing migraine-related stigma was assessed using a 12-item questionnaire (Migraine-Related Stigma [MiRS]), which included two factors: feeling that others perceived that migraine was used for "Secondary Gain" and feeling that others were "Minimizing Burden."

The researchers found that 41.1 percent of the 59,001 respondents with active migraine reported experiencing at least four monthly headache days, and 31.7 percent experienced migraine-related stigma often/very often. There was an increase observed in the proportion experiencing migraine-related stigma often/very often from 25.5 to 47.5 percent among those with fewer than four and 15 or more monthly headache days, respectively. The risk for increased disability was significant for each MiRS group versus the MiRS-Never group; the MiRS-Both (Secondary Gain and Minimizing Burden often/very often) group had a more than twofold increased risk (rate ratio, 2.68). There was an association seen between increased migraine-related stigma and increased disease burden across all monthly headache day categories for disability, interictal burden, and migraine-specific quality of life.

"Clarifying the mechanisms that link stigma to health outcomes could set the stage for interventions that may reduce the burdens of migraine across the full spectrum of headache frequency," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which funded the study.

Abstract/Full Text

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords